Shattuck Labs: Raymond James sees the DR3 antibody as a growth driver - Expert sees 130% price potential

Raymond James has assigned a "Strong Buy" rating to the stock of Shattuck Labs (STTK) and has set an ambitious price target of $18. The compound SL-325 targets the more stable DR3 receptor in the market for gastrointestinal diseases, which is worth over $20 billion. The capital resources ensure development until 2029; Phase 2b data for Crohn's disease are expected in the first half of 2028. Focus on inflammatory bowel diseases through targeted receptor blockade The business model of the biopharmaceutical company Shattuck Labs is centered around...